Acumen Pharmaceuticals Inc. has released a corporate presentation detailing progress in its pipeline targeting early Alzheimer’s disease. The company highlighted Sabirnetug (ACU193), a monoclonal antibody highly selective for toxic amyloid beta oligomers, with positive Phase 1 clinical trial results and topline results from the Phase 2 ALTITUDE-AD study expected in late 2026. Acumen also outlined its Enhanced Brain Delivery (EBD™) program, which aims to develop antibodies with improved blood-brain barrier penetration. Pre-clinical candidate data for EBD-ACU193 and EBD-ACU234 are anticipated in early 2026, with options to advance up to two development candidates for Alzheimer’s treatment. As of September 30, 2025, the company reported approximately $136 million in cash, cash equivalents, and marketable securities, with a projected cash runway into early 2027. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.